跳至主要内容
临床试验/NCT00437437
NCT00437437已完成1 期

Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb3 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2000年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
29
试验地点
3
主要终点
To determine the effect on pharmacokinetics of BMS-540215, the active metabolite of brivanib alaninate, when administered following a high fat meal versus administration in a fasted state

研究概览

简要总结

The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologic/cytologic diagnosis of advanced or metastatic solid tumors
  • 4/6 weeks since prior therapy

排除标准

  • Brain metastases
  • Second primary malignancy
  • Thromboembolic disease requiring full anticoagulation within 6 months
  • Inability to swallow or absorb oral therapy

研究组 & 干预措施

1

Experimental

干预措施: Brivanib (Drug)

结局指标

主要结局

To determine the effect on pharmacokinetics of BMS-540215, the active metabolite of brivanib alaninate, when administered following a high fat meal versus administration in a fasted state

时间窗: throughout the study

次要结局

  • To assess safety and tolerability of Brivanib alaninate when administered in a fasted state, or following a high fat meal(throughout the study)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验